S&P 500
5,975.13
+0.7%
+$39.19
DJI
42,512.17
+0.5%
+$206.69
NASDAQ
19,441.51
+1.0%
+$198.90
Bitcoin
106,216.00
+1.9%
+1,999.29
AAPL
$203.06
+0.7%
+$1.36
AMZN
$207.54
+0.4%
+$0.89
GOOG
$169.14
-0.7%
-$1.23
META
$670.29
-0.1%
-$0.61
MSFT
$462.85
+0.2%
+$0.88
NVDA
$141.72
+3.2%
+$4.34
TSLA
$354.18
+3.4%
+$11.49
Inventiva (NASDAQ: IVA)
$3.61
(6.5%)
$0.22
Price as of June 3, 2025, 12:35 p.m. ET
Inventiva Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Inventiva Company Info
Inventiva SA is a clinical-stage biopharmaceutical company, which focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis, or NASH, and other diseases with significant unmet medical need. It owns an in-house drug-discovery platform that develops internal oncology and fibrosis discovery pipeline with approaches centered on transcription factors, epigenetics targets, and nuclear receptors. The company was founded by Pierre Broqua and Frédéric Cren on October 27, 2011 and is headquartered in Daix, France.
News & Analysis
No articles found.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.